Multinational and domestic pharmaceutical companies are getting ready to compete in the KRW 100 billion COPD treatment market

The size of the entire COPD (Chronic Obstructive Pulmonary Disease) treatment market is estimated at approximately KRW 100 billion, and the two leading products are Seretide(GSK) and Spiriva(Boehringer Ingelheim). The top 10 products, including the two products, are occupying approximately 75% sales of the entire market.

Last year, Seretide and Spiriva recorded approximately KRW 30 billion and...